S3-Leitlinie Kolorektales Karzinom Version 1.0 – Juni 2013 AWMF-Registernummer: 021/007OL

C. Pox; S. Aretz; S. C. Bischoff; U. Graeven; M. Hass; P. Heußner; W. Hohenberger; A. Holstege; J. Hübner; F. Kolligs; M. Kreis; P. Lux; J. Ockenga; R. Porschen; S. Post; N. Rahner; A. Reinacher-Schick; J. F. Riemann; R. Sauer; A. Sieg; W. Scheppach; W. Schmitt; H. J. Schmoll; K. Schulmann; A. Tannapfel; W. Schmiegel

doi:10.1055/s-0033-1350264

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2013; 51(8): 753-854
DOI: 10.1055/s-0033-1350264

Leitlinie

S3-Leitlinie Kolorektales Karzinom Version 1.0 – Juni 2013 AWMF-Registernummer: 021/007OL

S3-Guideline Colorectal Cancer Version 1.0

C. Pox

¹Medizinische Klinik, Knappschaftskrankenhaus GmbH Bochum, Ruhr-Universität Bochum, Bochum

,

S. Aretz

²Institut für Humangenetik, Universitätsklinik Bonn, Bonn

,

S. C. Bischoff

³Institut f. Ernährungsmedizin/Prävention Universität Hohenheim, Stuttgart

,

U. Graeven

⁴Medizinische Klinik I, Krankenhaus St. Franziskus, Mönchengladbach

,

M. Hass

⁵Deutsche ILCO e.V., Bonn

,

P. Heußner

⁶Medizinische Klinik und Poliklinik III, Klinikum der Universität München, München

,

W. Hohenberger

⁷Chirurgische Klinik, Universitätsklinikum Erlangen, Erlangen

,

A. Holstege

⁸Medizinische Klinik I, Klinikum Landshut gGmbH, Landshut

,

J. Hübner

⁹Komplementäre Onkologie, Centrum für Tumorerkrankungen J. W. Goethe-Universität, Frankfurt

,

F. Kolligs

¹⁰Medizinische Klinik und Poliklinik II, Klinikum der Universität München, München

,

M. Kreis

¹¹Chirurgische Klinik I, Charité- Universität Berlin, Campus Benjamin Fränklin, Berlin

,

P. Lux

⁷Chirurgische Klinik, Universitätsklinikum Erlangen, Erlangen

,

J. Ockenga

¹²Medizinische Klinik II, Klinikum Bremen-Mitte, Bremen

,

R. Porschen

¹³Medizinische Klinik, Klinikum Bremen-Ost, Bremen

,

S. Post

¹⁴Chirurgische Klinik, Universitätsklinikum Mannheim GmbH, Mannheim

,

N. Rahner

¹⁵Institut f. Humangenetik u. Anthropologie, Heinrich Heine Universität, Düsseldorf

,

A. Reinacher-Schick

¹⁶Abteilung für Hämatologie/Onkologie, St. Josef Hospital Bochum, Ruhr-Universität Bochum, Bochum

,

J. F. Riemann

¹⁷Stiftung Lebensblicke, Ludwigshafen

,

R. Sauer

¹⁸Strahlenklinik, Universität Erlangen/Nürnberg, Erlangen

,

A. Sieg

¹⁹Gastroenterologische Schwerpunktpraxis, Heidelberg

,

W. Scheppach

²⁰Gastroenterologische Klinik, Stiftung Juliusspital Würzburg, Würzburg

,

W. Schmitt

²¹I. Med. Abteilung, Städtisches Krankenhaus München-Neuperlach, München

,

H. J. Schmoll

²²Klinik und Poliklinik für Innere Medizin IV, Universität Halle, Halle

,

K. Schulmann

²³Klinik für Innere Medizin, Klinikum Arnsberg, St. Johannes-Hospital, MVZ Arnsberg

,

A. Tannapfel

²⁴Pathologisches Institut der Ruhr Universität Bochum, Bochum

,

W. Schmiegel

¹Medizinische Klinik, Knappschaftskrankenhaus GmbH Bochum, Ruhr-Universität Bochum, Bochum

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Kirkegaard H et al. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ 2010; 341: c5504
2 Halle M, Schoenberg MH. Physical activity in the prevention and treatment of colorectal carcinoma. Dtsch Arztebl Int 2009; 106 (44) 722-727
3 Wolin KY et al. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009; 100 (04) 611-616
4 Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a meta-analysis. Br J Cancer 2011; 104 (05) 882-885
5 Wolin KY et al. Leisure-time physical activity patterns and risk of colon cancer in women. Int J Cancer 2007; 121 (12) 2776-2781
6 Friedenreich C et al. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2006; 15 (12) 2398-2407
7 Lubin F et al. Nutritional and lifestyle habits and water-fiber interaction in colorectal adenoma etiology. Cancer Epidemiol Biomarkers Prev 1997; 6 (02) 79-85
8 Giacosa A et al. Energy intake, overweight, physical exercise and colorectal cancer risk. Eur J Cancer Prev 1999; 8 (Suppl. 01) S53-S60
9 Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002; 132 (Suppl. 11) 3456S-3464S
10 Terry MB et al. Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2002; 11 (07) 622-629
11 Lee IM. Physical activity and cancer prevention – data from epidemiologic studies. Med Sci Sports Exerc 2003; 35 (11) 1823-1827
12 Wei EK et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer 2004; 108 (03) 433-442
13 Martinez ME et al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst 1999; 91 (11) 950-953
14 Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002; 31 (04) 925-943
15 Giovannucci E. Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence. J Womens Health (Larchmt) 2003; 12 (02) 173-182
16 Renehan AG et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371 (9612) 569-578
17 Pischon T et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98 (13) 920-931
18 Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev 2010; 11 (01) 19-30
19 Terry MB, Neugut AI. Cigarette smoking and the colorectal adenoma-carcinoma sequence: a hypothesis to explain the paradox. Am J Epidemiol 1998; 147 (10) 903-910
20 Almendingen K et al. Smoking and colorectal adenomas: a case-control study. Eur J Cancer Prev 2000; 9 (03) 193-203
21 Chao A et al. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst 2000; 92 (23) 1888-1896
22 Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10 (07) 725-731
23 Reid ME et al. Smoking exposure as a risk factor for prevalent and recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2003; 12 (10) 1006-1011
24 Botteri E et al. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 2008; 134 (02) 388-395
25 Botteri E et al. Smoking and colorectal cancer: a meta-analysis. JAMA 2008; 300 (23) 2765-2778
26 Miller PE et al. Dietary patterns and colorectal adenoma and cancer risk: a review of the epidemiological evidence. Nutr Cancer 2010; 62 (04) 413-424
27 Cottet V et al. Dietary patterns and the risk of colorectal adenoma recurrence in a European intervention trial. Eur J Cancer Prev 2005; 14 (01) 21-29
28 Mai V et al. Diet quality and subsequent cancer incidence and mortality in a prospective cohort of women. Int J Epidemiol 2005; 34 (01) 54-60
29 Sansbury LB et al. The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence. Am J Epidemiol 2009; 170 (05) 576-584
30 Wakai K et al. Dietary risk factors for colon and rectal cancers: a comparative case-control study. J Epidemiol 2006; 16 (03) 125-135
31 Beresford SA et al. Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295 (06) 643-654
32 Lanza E et al. The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev 2007; 16 (09) 1745-1752
33 Dahm CC et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst 2010; 102 (09) 614-626
34 Ishikawa H et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005; 116 (05) 762-767
35 Jacobs ET et al. Fiber, sex, and colorectal adenoma: results of a pooled analysis. Am J Clin Nutr 2006; 83 (02) 343-349
36 Park Y et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005; 294 (22) 2849-2857
37 Robertson DJ et al. Fat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol 2005; 100 (12) 2789-2795
38 Austin GL et al. Moderate alcohol consumption protects against colorectal adenomas in smokers. Dig Dis Sci 2008; 53 (01) 116-122
39 Cho E et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140 (08) 603-613
40 Mizoue T et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol 2008; 167 (12) 1397-1406
41 Moskal A et al. Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies. Int J Cancer 2007; 120 (03) 664-671
42 Chao A et al. Meat consumption and risk of colorectal cancer. JAMA 2005; 293 (02) 172-182
43 Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 2006; 119 (11) 2657-2664
44 Mathew A et al. Meat intake and the recurrence of colorectal adenomas. Eur J Cancer Prev 2004; 13 (03) 159-164
45 Norat T et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 2005; 97 (12) 906-916
46 Sinha R et al. Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res 2005; 65 (17) 8034-8041
47 Geelen A et al. Fish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. Am J Epidemiol 2007; 166 (10) 1116-1125
48 Sugawara Y et al. Fish consumption and the risk of colorectal cancer: the Ohsaki Cohort Study. Br J Cancer 2009; 101 (05) 849-854
49 Pot GK et al. Fish consumption and markers of colorectal cancer risk: a multicenter randomized controlled trial. Am J Clin Nutr 2009; 90 (02) 354-361
50 Je Y, Liu W, Giovannucci E. Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. Int J Cancer 2009; 124 (07) 1662-1668
51 Sun CL et al. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 2006; 27 (07) 1301-1309
52 Zhang X et al. Risk of colon cancer and coffee, tea, and sugar-sweetened soft drink intake: pooled analysis of prospective cohort studies. J Natl Cancer Inst 2010; 102 (11) 771-783
53 Foschi R et al. Citrus fruit and cancer risk in a network of case-control studies. Cancer Causes Control 2010; 21 (02) 237-242
54 Millen AE et al. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am J Clin Nutr 2007; 86 (06) 1754-1764
55 Koushik A et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 2007; 99 (19) 1471-1483
56 Limburg PJ et al. Prospective evaluation of trans-fatty acid intake and colorectal cancer risk in the Iowa Women's Health Study. Int J Cancer 2008; 123 (11) 2717-2719
57 Alexander DD et al. Meta-analysis of animal fat or animal protein intake and colorectal cancer. Am J Clin Nutr 2009; 89 (05) 1402-1409
58 Galeone C et al. Fried foods, olive oil and colorectal cancer. Ann Oncol 2007; 18 (01) 36-39
59 Nakamura T et al. Excessive fat restriction might promote the recurrence of colorectal tumors. Nutr Cancer 2010; 62 (02) 154-163
60 Larsson SC et al. Dietary acrylamide intake and risk of colorectal cancer in a prospective cohort of men. Eur J Cancer 2009; 45 (04) 513-516
61 Hogervorst JG et al. Dietary acrylamide intake is not associated with gastrointestinal cancer risk. J Nutr 2008; 138 (11) 2229-2236
62 Mucci LA, Wilson KM. Acrylamide intake through diet and human cancer risk. J Agric Food Chem 2008; 56 (15) 6013-6019
63 Mucci LA, Adami HO, Wolk A. Prospective study of dietary acrylamide and risk of colorectal cancer among women. Int J Cancer 2006; 118 (01) 169-173
64 Bjelakovic G et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297 (08) 842-857
65 Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2008; 1: CD003548
66 Wactawski-Wende J et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354 (07) 684-696
67 Sanjoaquin MA et al. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 2005; 113 (05) 825-828
68 Wu K et al. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr 2009; 90 (06) 1623-1631
69 Jaszewski R et al. Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J Gastroenterol 2008; 14 (28) 4492-4498
70 Cole BF et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297 (21) 2351-2359
71 Logan RF et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134 (01) 29-38
72 Grau MV et al. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst 2007; 99 (02) 129-136
73 Wallace K et al. Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst 2004; 96 (12) 921-5
74 Hartman TJ et al. The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 2005; 135 (02) 252-259
75 Lin J et al. Total magnesium intake and colorectal cancer incidence in women. Cancer Epidemiol Biomarkers Prev 2006; 15 (10) 2006-2009
76 Jacobs ET et al. Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 2004; 96 (22) 1669-1675
77 Peters U et al. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol Biomarkers Prev 2006; 15 (02) 315-320
78 Vinogradova Y et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133 (02) 393-402
79 Bertagnolli MM et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355 (09) 873-884
80 Arber N et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355 (09) 885-895
81 Baron JA et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131 (06) 1674-1682
82 Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010; 59 (11) 1572-1585
83 Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U. S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 146 (05) 361-364
84 Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369 (9573) 1603-1613
85 Rothwell PM et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377 (9759) 31-41
86 Chan AT et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294 (08) 914-923
87 Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U. S. Preventive Services Task Force. Ann Intern Med 2005; 142 (10) 855-860
88 Farquhar C et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009; 2: CD004143
89 Alberts DS et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97 (11) 846-853
90 DGGG. Hormontherapie (HT) in der Peri- und Postmenopause. 2009
91 Birkner BR. Evidence-based prevention of colorectal carcinoma. Dtsch Med Wochenschr 2003; 128 (49) 2598-2603
92 Winawer SJ et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112 (02) 594-642
93 Imperiale TF et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002; 346 (23) 1781-1785
94 Whitlock EP et al. Screening for colorectal cancer: a targeted, updated systematic review for the U. S. Preventive Services Task Force. Ann Intern Med 2008; 149 (09) 638-658
95 Stevens T, Burke CA. Colonoscopy screening in the elderly: when to stop?. Am J Gastroenterol 2003; 98 (08) 1881-1885
96 Kirchgatterer A et al. Colonoscopy and sigmoidoscopy in patients aged eighty years or older. Z Gastroenterol 2002; 40 (12) 951-956
97 Pox CP et al. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. Gastroenterology 2012; 142: 1460-1467
98 Zhang B, Fattah A, Nakama H. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening. Hepatogastroenterology 2000; 47 (32) 414-418
99 Winawer SJ et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329 (27) 1977-1981
100 Citarda F et al. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001; 48 (06) 812-815
101 Zauber AG et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366 (08) 687-696
102 Hol L et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59 (01) 62-68
103 Quintero E et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366 (08) 697-706
104 Bekanntmachungen: Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krebserkrankungen („Krebsfrüherkennungs-Richtlinien“). Dtsch Arztebl Int 2002; 1 (11) 518
105 Huppe D et al. Effectiveness of screening colonoscopy in a community-based study. Z Gastroenterol 2008; 46 (02) 193-200
106 Kahi CJ et al. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009; 7 (07) 770-775 quiz 711
107 Imperiale TF et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343 (03) 169-174
108 Lieberman DA et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343 (03) 162-168
109 Atkin W et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359 (9314) 1291-1300
110 Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155 (16) 1741-1748
111 Newcomb PA et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84 (20) 1572-1575
112 Selby JV et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326 (10) 653-657
113 Singh H et al. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol 2010; 105 (03) 663-673 ; quiz 674
114 Brenner H et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102 (02) 89-95
115 Brenner H et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154 (01) 22-30
116 Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. Gastrointest Endosc 2001; 53: 620-627
117 Rex DK et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112 (01) 24-28
118 Rex DK et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment]. Gastroenterology 1996; 111 (05) 1178-1181
119 Brenner H et al. Long-term risk of colorectal cancer after negative colonoscopy. J Clin Oncol 2011; 29 (28) 3761-3767
120 Bundesärztekammer: Richtlinien zur prädiktiven genetischen Diagnostik. Dt Ärztebl 2003; 100 (19) A1297-1305
121 Atkin WS et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375 (9726) 1624-1633
122 Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995; 123 (12) 904-910
123 Newcomb PA et al. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003; 95 (08) 622-625
124 Schoen RE et al. Results of repeat sigmoidoscopy 3 years after a negative examination. Jama 2003; 290 (01) 41-48
125 Burke CA, Elder K, Lopez R. Screening for colorectal cancer with flexible sigmoidoscopy: is a 5-yr interval appropriate? A comparison of the detection of neoplasia 3 yr versus 5 yr after a normal examination. Am J Gastroenterol 2006; 101 (06) 1329-1332
126 Winawer SJ et al. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85 (16) 1311-1318
127 Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345 (08) 555-560
128 Gondal G et al. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003; 38 (06) 635-642
129 Kato J et al. Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia. Clin Gastroenterol Hepatol 2009; 7 (12) 1341-1346
130 Eliakim R et al. Evaluation of the PillCam Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study. Endoscopy 2006; 38 (10) 963-70
131 Schoofs N, Deviere J, Van Gossum A. PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy 2006; 38 (10) 971-977
132 Van Gossum A et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009; 361 (03) 264-270
133 Spada C et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin Gastroenterol Hepatol 2010; 8 (06) 516-522
134 Gay G et al. Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy? Results of clinical comparison with colonoscopy in the perspective of colorectal cancer screening. Am J Gastroenterol 2010; 105 (05) 1076-1086
135 Eliakim R et al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. Endoscopy 2009; 41 (12) 1026-1031
136 Spada C et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest Endosc 2011; 74 (03) 581-589 e1
137 Mandel JS et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328 (19) 1365-1371
138 Zhu MM et al. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2010; 11 (03) 148-160
139 Rossum LG et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer 2011; 128 (08) 1908-1917
140 Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150 (03) 162-169
141 Brenner H, Haug U, Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. Int J Cancer 2010; 127 (07) 1643-1649
142 Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010; 105 (03) 682-690
143 Allison JE et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99 (19) 1462-1470
144 Park DI et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105 (09) 2017-2025
145 Launoy GD et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005; 115 (03) 493-496
146 Roon AH et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011; 9 (04) 333-339
147 Doran J, Hardcastle JD. Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing. Br J Surg 1982; 69 (12) 711-713
148 Ahlquist DA et al. Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 1989; 63 (09) 1826-1830
149 Macrae FA, St JohnDJ. Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-898
150 Greegor DH. Occult blood testing for detection of asymptomatic colon cancer. Cancer 1971; 28: 131-134
151 Hardcastle JD et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348 (9040) 1472-1477
152 Kronborg O et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348 (9040) 1467-1471
153 Hewitson P et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; 1: CD001216
154 Levin B, Hess K, Johnson C et al. A comparison of 3 fecal occult blood tests. Arch Intern Med 1997; 157 (09) 970-976
155 Gnauck R, Macrae FA, Fleisher M. How to perform the fecal occult blood test. CA Cancer J Clin 1984; 34: 134-147
156 Jaffe RM et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975; 83 (06) 824-826
157 Macrae FA et al. Optimal dietary conditions for hemoccult testing. Gastroenterology 1982; 82 (05) 899-903
158 Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Dig Dis Sci 1999; 44 (04) 756-760
159 Pignone M et al. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001; 4 (04) 150-156
160 Rossum LG et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135 (01) 82-90
161 Webendorfer S et al. Precautions for intestinal cancer in the workplace. An initiative for secondary prevention in the BASF joint-stock company. Dtsch Med Wochenschr 2004; 129 (06) 239-243
162 Mandel JS et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343 (22) 1603-1607
163 Traverso G et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346 (05) 311-320
164 Ahlquist DA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119 (05) 1219-1227
165 Dong SM et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93 (11) 858-865
166 Tagore KS et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3 (01) 47-53
167 Imperiale TF et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351 (26) 2704-2714
168 Ahlquist DA et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149 (07) 441-450 , W81
169 Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008; 99 (01) 133-135
170 Moslein G et al. Analysis of the statistical value of various commercially available stool tests – a comparison of one stool sample in correlation to colonoscopy. Dtsch Med Wochenschr 2010; 135 (12) 557-562
171 Haan MC et al. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. Eur Radiol 2011; 21 (08) 1747-1763
172 El-Maraghi RH, Kielar AZ. CT colonography versus optical colonoscopy for screening asymptomatic patients for colorectal cancer a patient, intervention, comparison, outcome (PICO) analysis. Acad Radiol 2009; 16 (05) 564-571
173 Pox CP, Schmiegel W. Role of CT colonography in colorectal cancer screening: risks and benefits. Gut 2010; 59 (05) 692-700
174 Frazier AL et al. Cost-effectiveness of screening for colorectal cancer in the general population. Jama 2000; 284 (15) 1954-1961
175 Geul KW et al. Prevention of colorectal cancer. Costs and effectiveness of sigmoidoscopy. Scand J Gastroenterol Suppl 1997; 223: 79-87
176 Inadomi JM. Update on the cost-effectiveness of screening for colorectal neoplasia. Curr Opin Gastroenterol 2003; 29: 44-50
177 Khandker RK et al. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000; 16 (03) 799-810
178 McGrath JS, Ponich TP, Gregor JC. Screening for colorectal cancer: the cost to find an advanced adenoma. Am J Gastroenterol 2002; 97 (11) 2902-2907
179 Norum J. Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy. Ann Oncol 1998; 9 (06) 613-618
180 Pignone M et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U. S. Preventive Services Task Force. Ann Intern Med 2002; 137 (02) 96-104
181 Sonnenberg A, Delco F. Cost-effectiveness of a single colonoscopy in screening for colorectal cancer. Arch Intern Med 2002; 162 (02) 163-168
182 Vijan S et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001; 111 (08) 593-601
183 Zauber AG et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U. S. Preventive Services Task Force. Ann Intern Med 2008; 149 (09) 659-669
184 Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011; 33 (01) 88-100
185 Sung JJ et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008; 57 (08) 1166-1176
186 Jasperson KW et al. Hereditary and familial colon cancer. Gastroenterology 2010; 138 (06) 2044-2058
187 Andrieu N et al. Familial relative risk of colorectal cancer: a population-based study. Eur J Cancer 2003; 39 (13) 1904-1911
188 Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96 (10) 2992-3003
189 Lichtenstein P et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343 (02) 78-85
190 Slattery ML et al. Family history and colorectal cancer: predictors of risk. Cancer Causes Control 2003; 14 (09) 879-887
191 Winawer S et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124 (02) 544-560
192 Bonelli L et al. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer 1988; 41 (04) 513-517
193 Fuchs CS et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331 (25) 1669-1674
194 Guillem JG et al. Clustering of colorectal cancer in families of probands under 40 years of age. Dis Colon Rectum 1996; 39 (09) 1004-1007
195 Guillem JG et al. Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study. Dis Colon Rectum 1992; 35 (06) 523-9
196 Kune GA, Kune S, Watson LF. The role of heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal Cancer Study. World J Surg 1989; 13 (01) 124-129
197 Rozen P et al. Family history of colorectal cancer as a marker of potential malignancy within a screening programm. Cancer 1987; 60 (02) 248-254
198 Sondergaard JO, Bulow S, Lynge E. Cancer incidence among parents of patients with colorectal cancer. Int J Cancer 1991; 47 (02) 202-206
199 St John DJ et al. Cancer risk in relatives of patients with common colorectal cancer. Ann Int Med 1993; 118 (10) 785-790
200 Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006; 42 (02) 216-227
201 Hall NR et al. Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk. Dis Colon Rectum 1996; 39 (07) 739-743
202 Hunt LM et al. Endoscopic screening of relatives of patients with colorectal cancer. Gut 1998; 42 (01) 71-75
203 Winawer SJ et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334 (02) 82-87
204 Ahsan H et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128 (11) 900-905
205 Nakama H et al. Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer. Eur J Cancer 2000; 36 (16) 2111-2114
206 Almendingen K, Hofstad B, Vatn MH. Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas?. Gut 2003; 52 (05) 747-751
207 Winawer SJ et al. Risk and surveillance of individuals with colorectal polyps. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1990; 68 (06) 789-795
208 Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326 (10) 658-662
209 Otchy DP et al. Metachronous colon cancer in persons who have had a large adenomatous polyp. Am J Gastroenterol 1996; 91 (03) 448-454
210 Stolck RU et al. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group. Gastroenterology 1998; 115 (01) 13-18
211 Noshirwani KC et al. Adenoma size and number are predictive of adenoma recurrence: implications for surveillance colonoscopy. Gastrointest Endosc 2000; 51: 433-437
212 Aldridge AJ, Simson JN. Histological assessment of colorectal adenomas by size. Are polyps less than 10 mm in size clinically important?. Eur J Surg 2001; 167 (10) 777-781
213 Avidan B et al. New occurrence and recurrence of neoplasms within 5 years of a screening colonoscopy. Am J Gastroenterol 2002; 97 (06) 1524-1529
214 Bertario L et al. Predictors of metachronous colorectal neoplasms in sporadic adenoma patients. Int J Cancer 2003; 105 (01) 82-87
215 Chen CD et al. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 2003; 88 (12) 1866-1873
216 Bensen S et al. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group. Am J Gastroenterol 1999; 94 (01) 194-199
217 Katalinic A, Raspe H, Waldmann A. Positive family history of colorectal cancer – use of a questionnaire. Z Gastroenterol 2009; 47 (11) 1125-1131
218 Baron JA et al. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial. J Natl Cancer Inst 2003; 95 (10) 717-722
219 Karnes WE. Epidemiology and etiology of sporadic colorectal adenocarcinoma. Current opinion in Gastroenterology 1994; 10: 19-26
220 Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348 (10) 883-890
221 Rothwell PM et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376 (9754) 1741-1750
222 Burt RW. Screening of patients with a positive family history of colorectal cancer. Gastrointest Endosc Clin N Am 1997; 7 (01) 65-79
223 Gilbert JM et al. Feasibility study of colonoscopy as the primary screening investigation in relatives of patients with colorectal cancer. Ann R Coll Surg Engl 2001; 83 (06) 415-419
224 Syrigos KN et al. Colonoscopy in asymptomatic individuals with a family history of colorectal cancer. Ann Surg Oncol 2002; 9 (05) 439-443
225 Bradshaw N et al. Colonoscopy surveillance of individuals at risk of familial colorectal cancer. Gut 2003; 52 (12) 1748-1751
226 Brenner H, Hoffmeister M, Haug U. Family history and age at initiation of colorectal cancer screening. Am J Gastroenterol 2008; 103 (09) 2326-2331
227 Waldmann A, Raspe H, Katalinic A. Colon cancer risk in persons at familial or hereditary risk aged < 55 years. Z Gastroenterol 2009; 47 (10) 1052-1058
228 Levin B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134 (05) 1570-1595
229 Engel C et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2010; 8 (02) 174-182
230 Dove-Edwin I et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005; 331 (7524) 1047
231 Duncan RE et al. The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis. Fam Cancer 2010; 9 (01) 27-35
232 Douma KF et al. Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. Psychooncology 2008; 17 (08) 737-745
233 Douma KF et al. Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psychooncology 2010; 19 (03) 289-298
234 Vasen HF et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34 (05) 424-425
235 Rodriguez-Bigas MA et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89 (23) 1758-1762
236 Schulmann K et al. Small bowel cancer risk in Lynch syndrome. Gut 2008; 57 (11) 1629-1630
237 Kate GL et al. Is surveillance of the small bowel indicated for Lynch syndrome families?. Gut 2007; 56 (09) 1198-1201
238 Schulmann K et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005; 128 (03) 590-599
239 der Post RS et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010; 47 (07) 464-470
240 Kastrinos F et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302 (16) 1790-1795
241 Win AK et al. Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study. J Clin Oncol 2012; 30: 958-964
242 Vasen HF et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19 (20) 4074-4080
243 Aarnio M et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64 (06) 430-433
244 Vasen HF et al. The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer 1996; 65 (04) 422-425
245 Kruse R et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998; 63 (01) 63-70
246 Umar A et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96 (04) 261-268
247 Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10 (04) 293-300
248 Deng G et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10 (01) 191-195
249 Domingo E et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41 (09) 664-668
250 Loughrey MB et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6 (03) 301-310
251 McGivern A et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004; 3 (02) 101-107
252 Levine AJ et al. Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry. Cancer Prev Res (Phila) 2012; 5 (02) 328-335
253 Foulkes WD. A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM 1995; 88 (12) 853-863
254 Lynch HT et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995; 76 (12) 2427-2433
255 Lynch HT, Smyrk TC. Classification of familial adenomatous polyposis: a diagnostic nightmare. Am J Hum Genet 1998; 62 (06) 1288-1289
256 Soravia C et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998; 62: 1290-1301
257 Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002; 45 (01) 127-134 ; discussion 134-136
258 Knudsen AL, Bisgaard ML, Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003; 2 (01) 43-55
259 Al-Tassan N et al. Inherited variants of MYH associated with somatic G:C → T:A mutations in colorectal tumors. Nat Genet 2002; 30 (02) 227-232
260 Cao Y et al. Challenge in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the literature. Am J Gastroenterol 2002; 97 (07) 1822-1827
261 Aretz S. The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes. Dtsch Arztebl Int 2010; 107 (10) 163-173
262 Aretz S, Genuardi M, Hes FJ. Clinical utility gene card for: MUTYH-associated polyposis (MAP), autosomal recessive colorectal adenomatous polyposis. Eur J Hum Genet 2013; 21
263 Sampson JR, Jones N. MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol 2009; 23 (02) 209-218
264 Morreau H, Riddel R, Aretz S. MUTYH-associated polyposis. In: Bosman FT, et al. Editors WHO Classification of Tumours of the Digestive System. Lyon: IARC/WHO Press; 2010: 156-159
265 Aretz S et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 2006; 119 (04) 807-814
266 Lubbe SJ et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009; 27 (24) 3975-3980
267 Cleary SP et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 2009; 136 (04) 1251-1260
268 Boparai KS et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 2008; 135 (06) 2014-2018
269 Vogt S et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009; 137 (06) 1976-1985
270 Papadopoulos N, Lindblom A. Molecular basis of HNPCC: mutations of MMR genes. Hum Mut 1997; 10: 89-99
271 Kuiper RP et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 2011; 32 (04) 407-414
272 Jarvinen HJ et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118 (05) 829-834
273 Vos tot Nederveen Cappel WH et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002; 45 (12) 1588-1594
274 Edelstein DL et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol 2011; 9 (04) 340-343
275 Renkonen-Sinisalo L et al. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000; 24 (02) 137-142
276 Huneburg R et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009; 41 (04) 316-322
277 Stoffel EM et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila) 2008; 1 (06) 470-475
278 Hurlstone DP et al. High magnification chromoscopic colonoscopy or high frequency 20 MHz mini probe endoscopic ultrasound staging for early colorectal neoplasia: a comparative prospective analysis. Gut 2005; 54 (11) 1585-1589
279 Aarnio M et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81 (02) 214-218
280 Dove-Edwin I et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94 (06) 1708-1712
281 Rijcken FE et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91 (01) 74-80
282 Renkonen-Sinisalo L et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007; 120 (04) 821-824
283 Vasen HF et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44 (06) 353-362
284 Goecke T et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 2006; 24 (26) 4285-4292
285 Burn J et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359 (24) 2567-2578
286 Burn J et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378 (9809) 2081-2087
287 Natarajan N et al. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 2010; 53 (01) 77-82
288 Kalady MF et al. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg 2010; 252 (03) 507-511 ; discussion 511-513
289 Parry S et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60 (07) 950-957
290 Stupart DA et al. Surgery for colonic cancer in HNPCC: total vs. segmental colectomy. Colorectal Dis 2011; 13 (12) 1395-1399
291 Schmeler KM et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354 (03) 261-269
292 Church JM et al. Teenagers with familial adenomatous polyposis: what is their risk for colorectal cancer?. Dis Colon Rectum 2002; 45 (07) 887-889
293 King JE et al. Care of patients and their families with familial adenomatous polyposis. Mayo Clin Proc 2000; 75 (01) 57-67
294 Bertario L et al. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol 1994; 10 (03) 225-234
295 Galle TS, Juel K, Bulow S. Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 1999; 34 (08) 808-812
296 Heiskanen I, Luostarinen T, Jarvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 2000; 35 (12) 1284-1287
297 Vasen HF et al. Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients. Gut 2001; 49 (02) 231-235
298 Bulow S. Results of national registration of familial adenomatous polyposis. Gut 2003; 52 (05) 742-746
299 Ficari F et al. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis. Br J Cancer 2000; 82 (02) 348-353
300 Bulow S. Clinical features in familial polyposis coli. Results of the Danish Polyposis Register. Dis Colon Rectum 1986; 29 (02) 102-107
301 De Cosse JJ et al. Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle Polyposis Group. Br J Surg 1992; 79 (12) 1372-1375
302 Nyam DC et al. Ileal pouch-anal canal anastomosis for familial adenomatous polyposis: early and late results. Ann Surg 1997; 226 (04) 514-519 ; discussion 519-521
303 Parc YR et al. Familial adenomatous polyposis: results after ileal pouch-anal anastomosis in teenagers. Dis Colon Rectum 2000; 43 (07) 893-898 ; discussion 898-902
304 Van Duijvendijk P et al. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis. Br J Surg 2000; 87 (05) 590-596
305 Church J et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 2003; 46 (09) 1175-1181
306 Will OC et al. Familial adenomatous polyposis and the small bowel: a loco-regional review and current management strategies. Pathol Res Pract 2008; 204 (07) 449-458
307 Spigelman AD et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2 (8666) 783-785
308 Burke CA et al. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999; 49 (03) 358-364
309 Matsumoto T et al. Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance. Am J Gastroenterol 2000; 95 (06) 1557-1562
310 Moozar KL et al. Slow progression of periampullary neoplasia in familial adenomatous polyposis. J Gastrointest Surg 2002; 6 (06) 831-837 ; discussion 837
311 Saurin JC et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc 2002; 55 (03) 342-347
312 Saurin JC et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22 (03) 493-498
313 Vasen HF et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997; 40: 716-719
314 Bulow S et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004; 53 (03) 381-386
315 Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 2001; 16 (02) 63-75
316 Norton ID et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002; 56 (02) 239-243
317 Kalady MF et al. Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg 2002; 6 (01) 82-87
318 Parc Y, Mabrut JY, Shields C. Surgical management of the duodenal manifestations of familial adenomatous polyposis. Br J Surg 2011; 98 (04) 480-484
319 Vos tot Nederveen Cappel WH et al. Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. Br J Surg 2003; 90 (06) 705-710
320 Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 1999; 31 (06) 412-416
321 Norton ID et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001; 96 (01) 101-106
322 Bleau BL, Gostout CJ. Endoscopic treatment of ampullary adenomas in familial adenomatous polyposis. J Clin Gastroenterol 1996; 22 (03) 237-241
323 Soravia C et al. Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 2000; 43 (03) 363-369
324 Bertario L et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21 (09) 1698-1707
325 Friedl W et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001; 48 (04) 515-521
326 Janinis J et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14 (02) 181-190
327 Tonelli F et al. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 2003; 89 (04) 391-396
328 Gega M et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24 (01) 102-105
329 Skapek SX et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 2007; 25 (05) 501-506
330 Latchford AR et al. A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 2006; 93 (10) 1258-1264
331 Möslein G. Current ideas in desmoid tumours: invited commentary. Fam Cancer 2006; 5: 287-288
332 Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996; 83 (11) 1494-1504
333 Nieuwenhuis MH et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011; 104 (01) 37-42
334 Huang K et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol 2009; 100 (07) 563-569
335 Salas S et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011; 29 (26) 3553-3558
336 Bulow C, Bulow S. Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis 1997; 12 (04) 240-242
337 Jarrar AM et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011; 253 (03) 515-521
338 Martayan A et al. Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation. J Endocrinol Invest 2010; 33 (09) 603-606
339 Herraiz M et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007; 5 (03) 367-373
340 Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner’s syndrome) and thyroid carcinoma. A case report and review of the literature. . Dig Dis Sci 1993; 38 (01) 185-190
341 Perrier ND et al. Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 1998; 22 (07) 738-742 ; discussion 743
342 Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet 1992; 43 (06) 1023-1025
343 Thomas D et al. Familial hepatoblastoma and APC gene mutations: renewed call for molecular research. Eur J Cancer 2003; 39 (15) 2200-2204
344 Aretz S et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?. Pediatr Blood Cancer 2006; 47 (06) 811-818
345 Vasen HF et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57 (05) 704-713
346 Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24 (01) 83-7
347 Labayle D et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101 (03) 635-639
348 Giardiello FM et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328 (18) 1313-1316
349 Cruz-Correa M et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002; 122 (03) 641-645
350 Winde G et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995; 38 (08) 813-830
351 Giardiello FM et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346 (14) 1054-1059
352 Steinbach G et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342 (26) 1946-1952
353 Phillips RK et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50 (06) 857-860
354 Solomon SD et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117 (16) 2104-2113
355 Matsuo S et al. Attenuated familial adenomatous polyposis associated with advanced rectal cancer in a 16-year-old boy: report of a case. Surg Today 2001; 31 (11) 1020-1023
356 Leggett BA et al. Severe upper gastrointestinal polyposis associated with sparse colonic polyposis in a familial adenomatous polyposis family with an APC mutation at codon 1520. Gut 1997; 41 (04) 518-521
357 Zwick A et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997; 113 (02) 659-663
358 Hofgartner WT et al. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol 1999; 94 (08) 2275-2281
359 Jones N et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 2009; 137 (02) 489-494 , 494 e1; quiz 725-726
360 Farrington SM et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 2005; 77 (01) 112-119
361 Nielsen M et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology 2009; 136 (02) 471-476
362 Nascimbeni R et al. Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis. Dis Colon Rectum 2010; 53 (12) 1670-1675
363 Nielsen M et al. Duodenal carcinoma in MUTYH-associated polyposis. J Clin Pathol 2006; 59 (11) 1212-1215
364 Zbuk KM, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol 2007; 4 (09) 492-502
365 Aretz S et al. High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 2005; 26 (06) 513-519
366 Hinds R et al. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr 2004; 39 (02) 219-220
367 Reid JD. Intestinal carcinoma in the Peutz-Jeghers syndrome. Jama 1974; 229 (07) 833-834
368 Burdick D, Prior JT. Peutz-Jeghers syndrome. A clinicopathologic study of a large family with a 27-year follow-up. Cancer 1982; 50 (10) 2139-2146
369 Giardiello FM et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987; 316 (24) 1511-1514
370 Foley TR, McGarrity TJ, Abt AB. Peutz-Jeghers syndrome: a clinicopathologic survey of the “Harrisburg family” with a 49-year follow-up. Gastroenterology 1988; 95 (06) 1535-1540
371 Spigelman AD, Murday V, Phillips RK. Cancer and the Peutz-Jeghers syndrome. Gut 1989; 30 (11) 1588-1590
372 Hizawa K et al. Neoplastic transformation arising in Peutz-Jeghers polyposis. Dis Colon Rectum 1993; 36: 953-957
373 Boardman LA et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128 (11) 896-899
374 Mehenni H et al. Cancer risks in LKB1 germline mutation carriers. Gut 2006; 55 (07) 984-990
375 Giardiello FM et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119 (06) 1447-1453
376 Hearle N et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006; 12 (10) 3209-3215
377 Sweet K et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005; 294 (19) 2465-2473
378 Aretz S et al. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. J Med Genet 2007; 44 (11) 702-709
379 Gallione CJ et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363 (9412) 852-859
380 Watanabe A et al. Familial juvenile polyposis of the stomach. Gastroenterology 1979; 77 (01) 148-151
381 Jass JR et al. Juvenile polyposis – a precancerous condition. Histopathology 1988; 13 (06) 619-630
382 Sassatelli R et al. Generalized juvenile polyposis with mixed pattern and gastric cancer. Gastroenterology 1993; 104 (03) 910-915
383 Coburn MC et al. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995; 2 (05) 386-391
384 Desai DC et al. Juvenile polyposis. Br J Surg 1995; 82 (01) 14-17
385 Delnatte C et al. Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. Am J Hum Genet 2006; 78 (06) 1066-1074
386 Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009; 11 (10) 687-694
387 Tan MH et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18 (02) 400-407
388 Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008; 27 (41) 5387-5397
389 Marsh DJ et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999; 8 (08) 1461-1472
390 Jeevaratnam P et al. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J Pathol 1996; 179 (01) 20-25
391 Leggett BA et al. Hyperplastic polyposis: association with colorectal cancer. Am J Surg Pathol 2001; 25 (02) 177-184
392 Renaut AJ, Douglas PR, Newstead GL. Hyperplastic polyposis of the colon and rectum. Colorectal Dis 2002; 4 (03) 213-215
393 Jaeger EE et al. An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome. Am J Hum Genet 2003; 72 (05) 1261-1267
394 Rozen P, Samuel Z, Brazowski E. A prospective study of the clinical, genetic, screening, and pathologic features of a family with hereditary mixed polyposis syndrome. Am J Gastroenterol 2003; 98 (10) 2317-2320
395 Beggs AD et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59 (07) 975-986
396 Dignass A et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 2011; 49 (09) 1276-1341
397 Collins PD et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006; 2: CD000279
398 Rutter MD et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130 (04) 1030-1038
399 Lutgens MW et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57 (09) 1246-1251
400 Lim CH et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52 (08) 1127-1132
401 Connell WR et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107 (04) 934-944
402 Claessen MM et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15 (09) 1331-1336
403 Soetikno RM et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56 (01) 48-54
404 Scarpa M et al. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 2007; 94 (05) 534-545
405 Hoffmann JC et al. Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 2008; 46 (09) 1094-1146
406 Rex DK et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U. S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2002; 97 (06) 1296-1308
407 Barclay RL et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355 (24) 2533-2541
408 Simmons DT et al. Impact of endoscopist withdrawal speed on polyp yield: implications for optimal colonoscopy withdrawal time. Aliment Pharmacol Ther 2006; 24 (06) 965-971
409 Lieberman D. A call to action – measuring the quality of colonoscopy. N Engl J Med 2006; 355 (24) 2588-2589
410 Pickhardt PJ et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349 (23) 2191-2200
411 Robertson DJ et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 2005; 129 (01) 34-41
412 Hosokawa O et al. Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer. Endoscopy 2003; 35 (06) 506-510
413 Bressler B et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology 2004; 127 (02) 452-456
414 Leaper M et al. Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Endoscopy 2004; 36 (06) 499-503
415 Pabby A et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 2005; 61 (03) 385-391
416 Cotton PB et al. Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. Jama 2004; 291 (14) 1713-1719
417 Rockey DC et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005; 365 (9456) 305-311
418 Halligan S et al. CT colonography in the detection of colorectal polyps and cancer: systematic review, meta-analysis, and proposed minimum data set for study level reporting. Radiology 2005; 237 (03) 893-904
419 Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med 2005; 142 (08) 635-650
420 Johnson CD et al. Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps. Clin Gastroenterol Hepatol 2004; 2 (04) 314-321
421 Purkayastha S et al. Magnetic resonance colonography versus colonoscopy as a diagnostic investigation for colorectal cancer: a meta-analysis. Clin Radiol 2005; 60 (09) 980-989
422 Hartmann D et al. Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy. Radiology 2006; 238 (01) 143-149
423 Florie J et al. MR colonography with limited bowel preparation compared with optical colonoscopy in patients at increased risk for colorectal cancer. Radiology 2007; 243 (01) 122-131
424 Morrin MM et al. Virtual colonoscopy: a kinder, gentler colorectal cancer screening test?. Lancet 1999; 354 (9184) 1048-1049
425 Morrin MM et al. Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions. Dis Colon Rectum 2000; 43 (03) 303-311
426 Neri E et al. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy. Radiology 2002; 223 (03) 615-619
427 Hartmann D et al. Incomplete conventional colonoscopy: magnetic resonance colonography in the evaluation of the proximal colon. Endoscopy 2005; 37 (09) 816-820
428 Arora A, Singh P. Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield. Gastrointest Endosc 2004; 60 (03) 408-413
429 Karajeh MA, Sanders DS, Hurlstone DP. Colonoscopy in elderly people is a safe procedure with a high diagnostic yield: a prospective comparative study of 2000 patients. Endoscopy 2006; 38 (03) 226-230
430 Kiesslich R et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124 (04) 880-888
431 Hurlstone DP et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective “back-to-back” endoscopic study. Am J Gastroenterol 2005; 100 (10) 2167-2173
432 Hurlstone DP et al. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 2005; 37 (12) 1186-1192
433 Lee JH et al. Detection of colorectal adenomas by routine chromoendoscopy with indigocarmine. Am J Gastroenterol 2003; 98 (06) 1284-1288
434 Hurlstone DP et al. Detecting diminutive colorectal lesions at colonoscopy: a randomised controlled trial of pan-colonic versus targeted chromoscopy. Gut 2004; 53 (03) 376-380
435 Trecca A et al. Advanced diagnostic tools: virtual colonoscopy and magnifying chromoendoscopy. Tech Coloproctol 2004; 8 (Suppl. 02) s279-s282
436 Lapalus MG et al. Does chromoendoscopy with structure enhancement improve the colonoscopic adenoma detection rate?. Endoscopy 2006; 38 (05) 444-448
437 Kudo S et al. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. World J Surg 2000; 24 (09) 1081-1090
438 Kiesslich R et al. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. Endoscopy 2001; 33 (12) 1001-1006
439 Kudo S et al. Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy 2001; 33 (04) 367-373
440 Brooker JC et al. Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 2002; 56 (03) 333-338
441 Eisen GM et al. High-resolution chromoendoscopy for classifying colonic polyps: a multicenter study. Gastrointest Endosc 2002; 55 (06) 687-694
442 Tsuda S et al. Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study. Gut 2002; 51 (04) 550-555
443 Bianco MA et al. Predictive value of magnification chromoendoscopy for diagnosing invasive neoplasia in nonpolypoid colorectal lesions and stratifying patients for endoscopic resection or surgery. Endoscopy 2006; 38 (05) 470-476
444 Kato S et al. Magnifying colonoscopy as a non-biopsy technique for differential diagnosis of non-neoplastic and neoplastic lesions. World J Gastroenterol 2006; 12 (09) 1416-1420
445 Hurlstone DP et al. Endoscopic morphological anticipation of submucosal invasion in flat and depressed colorectal lesions: clinical implications and subtype analysis of the kudo type V pit pattern using high-magnification-chromoscopic colonoscopy. Colorectal Dis 2004; 6 (05) 369-375
446 Hurlstone DP et al. Efficacy of high magnification chromoscopic colonoscopy for the diagnosis of neoplasia in flat and depressed lesions of the colorectum: a prospective analysis. Gut 2004; 53 (02) 284-290
447 Chiu HM et al. A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut 2007; 56 (03) 373-379
448 Dekker E et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007; 39 (03) 216-221
449 Su MY et al. Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps. Am J Gastroenterol 2006; 101 (12) 2711-2716
450 Kiesslich R et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127 (03) 706-713
451 Nivatvongs S. Complications in colonoscopic polypectomy. An experience with 1,555 polypectomies. Dis Colon Rectum 1986; 29 (12) 825-830
452 Reiertsen O et al. Complications of fiberoptic gastrointestinal endoscopy – five years’ experience in a central hospital. Endoscopy 1987; 19 (01) 1-6
453 Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15 (04) 347-351
454 Waye JD, Kahn O, Auerbach ME. Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996; 6 (02) 343-377
455 Hsieh YH et al. Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study. Hepatogastroenterology 2001; 48 (41) 1379-1382
456 Karita M, Cantero D, Okita K. Endoscopic diagnosis and resection treatment for flat adenoma with severe dysplasia. Am J Gastroenterol 1993; 88 (09) 1421-1423
457 Kudo S et al. Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg 1997; 21 (07) 694-701
458 Heldwein W et al. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy 2005; 37 (11) 1116-1122
459 Di Giorgio P et al. Detachable snare versus epinephrine injection in the prevention of postpolypectomy bleeding: a randomized and controlled study. Endoscopy 2004; 36 (10) 860-863
460 Dobrowolski S et al. Prophylactic submucosal saline-adrenaline injection in colonoscopic polypectomy: prospective randomized study. Surg Endosc 2004; 18 (06) 990-993
461 Katsinelos P et al. Endoloop-assisted polypectomy for large pedunculated colorectal polyps. Surg Endosc 2006; 20 (08) 1257-1261
462 Paspatis GA et al. A prospective, randomized comparison of adrenaline injection in combination with detachable snare versus adrenaline injection alone in the prevention of postpolypectomy bleeding in large colonic polyps. Am J Gastroenterol 2006; 101 (12) 2805 ; quiz 2913
463 Shioji K et al. Prophylactic clip application does not decrease delayed bleeding after colonoscopic polypectomy. Gastrointest Endosc 2003; 57 (06) 691-694
464 Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest Endosc 1994; 40 (04) 458-462
465 Hui AJ et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59 (01) 44-48
466 Yousfi M et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99 (09) 1785-1789
467 Ernst A et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006; 129 (03) 734-737
468 Hurlstone DP et al. A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery. Colorectal Dis 2005; 7 (04) 339-344
469 Gondal G et al. Biopsy of colorectal polyps is not adequate for grading of neoplasia. Endoscopy 2005; 37 (12) 1193-1197
470 Waye JD et al. Small colon polyps. Am J Gastroenterol 1988; 83 (02) 120-122
471 O’Brien MJ et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98 (02) 371-379
472 Nusko G et al. Risk of invasive carcinoma in colorectal adenomas assessed by size and site. Int J Colorectal Dis 1997; 12 (05) 267-271
473 Bond JH. Clinical relevance of the small colorectal polyp. Endoscopy 2001; 33 (05) 454-457
474 Arumugam PJ et al. Severe dysplastic lesions in the colon – how aggressive should we be?. Colorectal Dis 2002; 4 (05) 345-347
475 Gschwantler M et al. High-grade dysplasia and invasive carcinoma in colorectal adenomas: a multivariate analysis of the impact of adenoma and patient characteristics. Eur J Gastroenterol Hepatol 2002; 14 (02) 183-188
476 Burton S et al. Reliability of pre-operative biopsies in the histological grading of colorectal adenocarcinomas. Ann R Coll Surg Engl 2003; 85 (01) 23-25
477 Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classification of Tumours. ed. Lyon: IARC Press; 2000
478 Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50 (01) 113-130
479 Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50 (01) 131-150
480 Deinlein P et al. Risk factors for lymphatic metastasis from pT1 colorectal adenocarcinoma. Pathologe 2003; 24 (05) 387-393
481 Hermanek P. Polypectomy in the colorectum: histological and oncological aspects. Endoscopy 1983; 15: 158-161
482 Kikuchi R et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995; 38 (12) 1286-1295
483 Okuyama T, Oya M, Ishikawa H. Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002; 45 (05) 628-634
484 Fruhmorgen P et al. Endoscopic Therapy of Early Colorectal Cancer (pT1) – A Prospective Study. Z Gastroenterol 2003; 41 (08) 703-710
485 Frühmorgen P et al. Kolorektale Polypen. In: Empfehlungen der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) für die Durchführung endoskopischer Untersuchungen. 2000: 127-134
486 Okabe S et al. Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. J Gastrointest Surg 2004; 8 (08) 1032-1039 ; discussion 1039-1040
487 Yamamoto S et al. The risk of lymph node metastasis in T1 colorectal carcinoma. Hepatogastroenterology 2004; 51 (58) 998-1000
488 Hassan C et al. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum 2005; 48 (08) 1588-1596
489 Ueno H et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127 (02) 385-394
490 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1 2002. Gastrointest Endosc 2003; 58 (Suppl. 06) S3-S43
491 Nascimbeni R et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002; 45 (02) 200-206
492 Seitz U et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004; 47 (11) 1789-1796
493 Provenzale D et al. Risk for colon adenomas in patients with rectosigmoid hyperplastic polyps. Ann Intern Med 1990; 113: 760-763
494 Rex DK et al. Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects. Gastroenterology 1992; 102: 317-319
495 Sciallero S et al. Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. Gastrointest Endosc 1997; 46 (02) 124-130
496 Koide N et al. A case of hyperplastic polyposis of the colon with adenocarcinomas in hyperplastic polyps after long-term follow-up. Endoscopy 2002; 34 (06) 499-502
497 Bressler B et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 2007; 132 (01) 96-102
498 Sawhney MS et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006; 131 (06) 1700-1705
499 Winawer SJ et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130 (06) 1872-1885
500 Higaki S et al. Long-term follow-up of large flat colorectal tumors resected endoscopically. Endoscopy 2003; 35 (10) 845-849
501 Regula J et al. Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study. Endoscopy 2003; 35 (03) 212-218
502 Seitz U et al. Long-term results of endoscopic removal of large colorectal adenomas. Endoscopy 2003; 35 (08) S41-S44
503 Boix J et al. Endoscopic removal of large sessile colorectal adenomas: is it safe and effective?. Dig Dis Sci 2007; 52 (03) 840-844
504 Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348 (10) 891-899
505 Benamouzig R et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125 (02) 328-336
506 Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003; 348 (10) 879-880
507 Bresalier RS et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352 (11) 1092-1102
508 Solomon SD et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352 (11) 1071-1080
509 Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006; 355 (09) 950-952
510 Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2005; 3: CD003548
511 Fielding LP et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 1991; 6 (04) 325-344
512 Soreide O et al. International standardization and documentation of the treatment of rectal cancer. In: Soreide O, Norstein J, , (eds) Rectal cancer surgery. Optimisation – standardization – documentation. Berlin Heidelberg New York.: Springer; 1997: 405-445
513 UICC. TNM Classification of Malignant Tumours. Sobin LH, Wittekind C, (ed.) 6th ed. New York: John Wiley & Sons; 2002
514 Adjuvant therapy for patients with colon and rectal cancer. Jama 1990; 264 (11) 1444-1450
515 Nelson H et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93 (08) 583-596
516 Pilipshen SJ et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53 (06) 1354-1362
517 Burton S et al. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. Br J Cancer 2006; 94 (03) 351-357
518 Segelman J et al. Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Dis 2009; 11 (07) 768-774
519 MacDermid E et al. Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis 2009; 11 (03) 291-295
520 Barillari P et al. Effect of preoperative colonoscopy on the incidence of synchronous and metachronous neoplasms. Acta Chir Scand 1990; 156 (02) 163-166
521 Faivre J. Endoscopic monitoring after excision of colorectal cancer. J Chir (Paris) 1997; 134 (07) 283-285
522 Chen HS, Sheen-Chen SM. Synchronous and “early” metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon Rectum 2000; 43 (08) 1093-1099
523 Floriani I et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31 (01) 19-31
524 Rafaelsen SR, Jakobsen A. Contrast-enhanced ultrasound vs. multidetector-computed tomography for detecting liver metastases in colorectal cancer: a prospective, blinded, patient-by-patient analysis. Colorectal Dis 2011; 13 (04) 420-425
525 Quaia E et al. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol 2006; 16 (07) 1599-1609
526 Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257 (03) 674-684
527 Mainenti PP et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom Imaging 2010; 35 (05) 511-521
528 McAndrew MR, Saba AK. Efficacy of routine preoperative computed tomography scans in colon cancer. Am Surg 1999; 65 (03) 205-208
529 Barton JB et al. The utility of routine preoperative computed tomography scanning in the management of veterans with colon cancer. Am J Surg 2002; 183 (05) 499-503
530 Dighe S et al. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. Clin Radiol 2010; 65 (09) 708-719
531 Abdel-Nabi H et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206 (03) 755-760
532 Akiyoshi T et al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis 2009; 11 (05) 464-469
533 Furukawa H et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006; 55 (07) 1007-1011
534 Kam MH et al. Comparison of magnetic resonance imaging-fluorodeoxy-glucose positron emission tomography fusion with pathological staging in rectal cancer. Br J Surg 2010; 97 (02) 266-268
535 Kinner S et al. Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging 2007; 32 (05) 606-612
536 Llamas-Elvira JM et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2007; 34 (06) 859-867
537 Ono K et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009; 29 (02) 336-340
538 Tateishi U et al. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging 2007; 34 (10) 1627-1634
539 Veit-Haibach P et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006; 296 (21) 2590-2600
540 Bassi MC et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70 (05) 1423-1426
541 Davey K et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 2008; 51 (07) 997-1003
542 Gearhart SL et al. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006; 13 (03) 397-404
543 Kantorova I et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003; 44 (11) 1784-1788
544 Nagata K et al. PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum 2008; 51 (06) 882-890
545 Park IJ et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006; 32 (09) 941-947
546 Paskeviciute B et al. Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer. Strahlenther Onkol 2009; 185 (04) 260-265
547 Ruers TJ et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009; 50 (07) 1036-1041
548 Moulton CA. An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). J Clin Oncol 2011; abstr 3520
549 Glazer ES et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145 (04) 340-345 ; discussion 345
550 Lubezky N et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007; 11 (04) 472-478
551 Spatz J et al. Neoadjuvant chemotherapy affects staging of colorectal liver metastasis – a comparison of PET, CT and intraoperative ultrasound. Int J Colorectal Dis 2011; 26 (02) 165-171
552 IQWIG. Positronenemissionstomographie (PET und PET/CT) bei rezidivierendem kolorektalen Karzinom – Vorbericht (vorläufige Nutzenbewertung). 2011
553 Patel S et al. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Ann Surg 2011; 253 (04) 666-671
554 Taylor RA, Akhurst TJ, Yuman F. Evaluation with positron emission tomography before hepatic resection for metastatic colorectal cancer improves survival in patients with a high clinical risk score. 2007 Gastrointestinal Cancers Symposium, Abstract No: 240, 2007.
555 Adie S et al. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?. ANZ J Surg 2009; 79 (05) 358-361
556 Levy M et al. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma 2008; 55 (02) 138-1342
557 Lewis MR et al. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall. Gynecol Oncol 2007; 105 (02) 395-398
558 Chen CC et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?. J Surg Res 2005; 124 (02) 169-174
559 Merkel S et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16 (05) 298-304
560 Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008; 26 (02) 303-312
561 Bipat S et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging – a meta-analysis. Radiology 2004; 232 (03) 773-783
562 Puli SR et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. Ann Surg Oncol 2009; 16 (05) 1255-1265
563 Ahmetoglu A et al. MDCT with multiplanar reconstruction in the preoperative local staging of rectal tumor. Abdom Imaging 2011; 36 (01) 31-37
564 Kim CK et al. Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging. Eur Radiol 2006; 16 (05) 972-980
565 Kim YW et al. A prospective comparison study for predicting circumferential resection margin between preoperative MRI and whole mount sections in mid-rectal cancer: significance of different scan planes. Eur J Surg Oncol 2008; 34 (06) 648-654
566 Kim YW et al. Factors related to preoperative assessment of the circumferential resection margin and the extent of mesorectal invasion by magnetic resonance imaging in rectal cancer: a prospective comparison study. World J Surg 2009; 33 (09) 1952-1960
567 Matsuoka H et al. MRI diagnosis of mesorectal lymph node metastasis in patients with rectal carcinoma. what is the optimal criterion? Anticancer Res 2004; 24 (06) 4097-4101
568 Wolberink SV et al. Multislice CT as a primary screening tool for the prediction of an involved mesorectal fascia and distant metastases in primary rectal cancer: a multicenter study. Dis Colon Rectum 2009; 52 (05) 928-934
569 Purkayastha S et al. Magnetic resonance colonography vs. computed tomography colonography for the diagnosis of colorectal cancer: an indirect comparison. Colorectal Dis 2007; 9 (02) 100-111
570 Torzilli G et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg 2005; 9 (08) 1148-1153 ; discussion 1153-1154
571 Zirngibl H, Husemann B, Hermanek P. Intraoperative spillage of tumor cells in surgery for rectal cancer. Dis Colon Rectum 1990; 33 (07) 610-614
572 Cahill RA, Leroy J, Marescaux J. Could lymphatic mapping and sentinel node biopsy provide oncological providence for local resectional techniques for colon cancer? A review of the literature. BMC Surg 2008; 8: 17
573 Wiese D et al. Ultrastaging of sentinel lymph nodes (SLNs) vs. non-SLNs in colorectal cancer – do we need both?. Am J Surg 2010; 199 (03) 354-358 ; discussion 358
574 Goligher JC. Incidence and pathology of carcinoma of the colon and rectum. In: Surgery of the anus, rectum and colon. London: Balliére Tindall; 1984: 445
575 Toyota S, Ohta H, Anazawa S. Rationale for extent of lymph node dissection for right colon cancer. Dis Colon Rectum 1995; 38 (07) 705-711
576 Tan KY et al. Distribution of the first metastatic lymph node in colon cancer and its clinical significance. Colorectal Dis 2010; 12 (01) 44-47
577 Lan YT et al. Significance of lymph node retrieval from the terminal ileum for patients with cecal and ascending colonic cancers. Ann Surg Oncol 2011; 18 (01) 146-152
578 Chang GJ et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99 (06) 433-441
579 Le VoyerTE et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21 (15) 2912-2919
580 Van Damme JP. Vascular anatomy in abdominal surgery. Stuttgart: Thieme; 1990
581 Kanemitsu Y et al. Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery. Br J Surg 2006; 93 (05) 609-615
582 Chin CC et al. Carcinoma obstruction of the proximal colon cancer and long-term prognosis – obstruction is a predictor of worse outcome in TNM stage II tumor. Int J Colorectal Dis 2010; 25 (07) 817-822
583 Hohenberger W et al. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation – technical notes and outcome. Colorectal Dis 2009; 11 (04) 354-364 ; discussion 364-365
584 West NP et al. Multicentre experience with extralevator abdominoperineal excision for low rectal cancer. Br J Surg 2010; 97 (04) 588-599
585 Bertelsen CA et al. Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision?. Colorectal Dis 2011; 13 (10) 1123-1129
586 (NICE). N.I.f.C.E. Radiofrequency ablation for the treatment of colorectal metastases in the liver. London: 2011
587 Kim KH et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 2011; 81 (01) 25-34
588 Mulier S et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol 2008; 15 (01) 144-157
589 (NICE). N.I.f.C.E. Selective internal radiation therapy for colorectal metastases in the liver. London: 2011
590 Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009; 4: CD007045
591 Christophi C et al. Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy. World J Surg 2004; 28 (10) 987-994
592 Wietzke-Braun P et al. Quality of life and outcome of ultrasound-guided laser interstitial thermo-therapy for non-resectable liver metastases of colorectal cancer. Eur J Gastroenterol Hepatol 2004; 16 (04) 389-395
593 Abcarian H, Pearl RK. Simple technique for high ligation of the inferior mesenteric artery and vein. Dis Colon Rectum 1991; 34 (12) 1138
594 Buunen M et al. Level of arterial ligation in total mesorectal excision (TME): an anatomical study. Int J Colorectal Dis 2009; 24 (11) 1317-1320
595 Pezim ME, Nicholls RJ. Survival after high or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer. Ann Surg 1984; 200 (06) 729-733
596 Surtees P, Ritchie JK, Phillips RK. High versus low ligation of the inferior mesenteric artery in rectal cancer. Br J Surg 1990; 77 (06) 618-621
597 Slanetz CA Jr, Grimson R. Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer. Dis Colon Rectum 1997; 40 (10) 1205-1218 ; discussion 1218-1219
598 Lange MM et al. Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review. Dis Colon Rectum 2008; 51 (07) 1139-1145
599 Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery – the clue to pelvic recurrence?. Br J Surg 1982; 69 (10) 613-616
600 Bokey EL et al. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. Br J Surg 1999; 86 (09) 1164-1170
601 Hermanek PJ. Multiviszerale Resektion beim kolorektalen Karzinom. Erfahrungen der SGKRK-Studie. Langenbecks Arch Surg 1992; Kongressband: 95-100
602 Havenga K et al. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg 1996; 182 (06) 495-502
603 Enker WE et al. Abdominoperineal resection via total mesorectal excision and autonomic nerve preservation for low rectal cancer. World J Surg 1997; 21 (07) 715-720
604 Georgiou P et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol 2009; 10 (11) 1053-1062
605 Gohl J, Hohenberger W, Merkel S. Lymph node dissection in rectal carcinoma: TME and what else?. Onkologie 2009; 32 (01) 57-61
606 Mortenson MM et al. Total mesorectal excision and pelvic node dissection for rectal cancer: an appraisal. Surg Oncol Clin N Am 2007; 16 (01) 177-197
607 Koch M et al. Is the lateral lymph node compartment relevant?. Recent Results Cancer Res 2005; 165: 40-45
608 Scott N et al. Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. Br J Surg 1995; 82 (08) 1031-1033
609 Reynolds JV et al. Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Br J Surg 1996; 83 (08) 1112-1115
610 Hida J et al. Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision. J Am Coll Surg 1997; 184 (06) 584-588
611 Zaheer S et al. Surgical treatment of adenocarcinoma of the rectum. Ann Surg 1998; 227 (06) 800-811
612 Leong AF. Selective total mesorectal excision for rectal cancer. Dis Colon Rectum 2000; 43 (09) 1237-1240
613 Heald RJ, Karanjia ND. Results of radical surgery for rectal cancer. World J Surg 1992; 16 (05) 848-857
614 Enker WE. Total mesorectal excision – the new golden standard of surgery for rectal cancer. Ann Med 1997; 29 (02) 127-133
615 Lazorthes F et al. Distal intramural spread of carcinoma of the rectum correlated with lymph nodal involvement. Surg Gynecol Obstet 1990; 170 (01) 45-48
616 Kwok SP et al. Prospective analysis of the distal margin of clearance in anterior resection for rectal carcinoma. Br J Surg 1996; 83 (07) 969-972
617 Andreola S et al. Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Dis Colon Rectum 1997; 40 (01) 25-29
618 Goldstein NS, Soman A, Sacksner J. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage. Am J Clin Pathol 1999; 111 (03) 349-351
619 Kiran RP, Lian L, Lavery IC. Does a subcentimeter distal resection margin adversely influence oncologic outcomes in patients with rectal cancer undergoing restorative proctectomy?. Dis Colon Rectum 2011; 54 (02) 157-163
620 Rutkowski A et al. Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe?. Ann Surg Oncol 2008; 15 (11) 3124-3131
621 Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev 2008; 2: CD006040
622 Fazio VW et al. A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers. Ann Surg 2007; 246 (03) 481-488 ; discussion 488-490
623 Liao C et al. Meta-analysis of the colon J-pouch vs. transverse coloplasty pouch after anterior resection for rectal cancer. Colorectal Dis 2010; 12 (07) 624-631
624 Siddiqui MR et al. A meta-analysis comparing side to end with colonic J-pouch formation after anterior resection for rectal cancer. Tech Coloproctol 2010; 14 (02) 113-123
625 Hida J et al. Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Prospective randomized study for determination of optimum pouch size. Dis Colon Rectum 1996; 39 (09) 986-991
626 Hohenberger W et al. Neoadjuvant radiochemotherapy for rectal cancer. Chirurg 2009; 80 (04) 294-302
627 Artioukh DY. Controversial aspects of rectal cancer surgery following preoperative chemoradiation. Colorectal Dis 2010; 12 (Suppl. 02) 25-29
628 Habr-Gama A et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240 (04) 711-717 ; discussion 717-718
629 Tekkis PP et al. Comparison of circumferential margin involvement between restorative and nonrestorative resections for rectal cancer. Colorectal Dis 2005; 7 (04) 369-374
630 Nagtegaal ID et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005; 23 (36) 9257-9264
631 Nisar PJ, Scott HJ. Myocutaneous flap reconstruction of the pelvis after abdominoperineal excision. Colorectal Dis 2009; 11 (08) 806-816
632 Montedori A et al. Covering ileo- or colostomy in anterior resection for rectal carcinoma. Cochrane Database Syst Rev 2010; 5: CD006878
633 Lindgren R et al. What is the risk for a permanent stoma after low anterior resection of the rectum for cancer? A six-year follow-up of a multicenter trial. Dis Colon Rectum 2011; 54 (01) 41-47
634 Klink CD et al. Protective ileostoma versus protective transverse stoma. What evidence is available?. Chirurg 2010; 81 (11) 974-977
635 Rondelli F et al. Loop ileostomy versus loop colostomy for fecal diversion after colorectal or coloanal anastomosis: a meta-analysis. Int J Colorectal Dis 2009; 24 (05) 479-488
636 Bass EM et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome?. Dis Colon Rectum 1997; 40 (04) 440-442
637 Millan M et al. Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units. Colorectal Dis 2010; 12 (07) e88-e92
638 Chaudhri S et al. Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial. Dis Colon Rectum 2005; 48 (03) 504-509
639 Hermanek P, Marzoli GP. Lokale Therapie des Rektumkarzinoms. Verfahren in kurativer Intention. Berlin Heidelberg Ney York Tokyo: Springer; 1994
640 Winde G et al. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996; 39 (09) 969-976
641 Sengupta S, Tjandra JJ. Local excision of rectal cancer: what is the evidence?. Dis Colon Rectum 2001; 44 (09) 1345-1361
642 Matzel KE, Merkel S, Hohenberger W. Lokale Therapieprinzipien beim Rektumkarzinom. Chirurg 2003; 74 (10) 897-904
643 Ptok H et al. Oncological outcome of local vs. radical resection of low-risk pT1 rectal cancer. Arch Surg 2007; 142 (07) 649-655 ; discussion 656
644 You YN et al. Is the increasing rate of local excision for stage I rectal cancer in the United States justified? A nationwide cohort study from the National Cancer Database. Ann Surg 2007; 245 (05) 726-733
645 Moore JS et al. Transanal endoscopic microsurgery is more effective than traditional transanal excision for resection of rectal masses. Dis Colon Rectum 2008; 51 (07) 1026-1030 ; discussion 1030-1031
646 Sgourakis G et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg 2011; 77 (06) 761-772
647 Bach SP et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg 2009; 96 (03) 280-290
648 Glimelius B, Pahlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 05) v82-v86
649 Suppiah A et al. Transanal endoscopic microsurgery in early rectal cancer: time for a trial?. Colorectal Dis 2008; 10 (04) 314-327 ; discussion 327-329
650 Valentini V et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009; 92 (02) 148-163
651 Hahnloser D et al. Immediate radical resection after local excision of rectal cancer: an oncologic compromise?. Dis Colon Rectum 2005; 48 (03) 429-437
652 Schwenk W et al. Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005; 3: CD003145
653 Liang Y et al. Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence. Eur J Surg Oncol 2008; 34 (11) 1217-1224
654 Kuhry E et al. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008; 2: CD003432
655 Guillou PJ et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365 (9472) 1718-1726
656 Jayne DG et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 2010; 97 (11) 1638-1645
657 Kwak JM et al. Robotic vs. laparoscopic resection of rectal cancer: short-term outcomes of a case-control study. Dis Colon Rectum 2011; 54 (02) 151-156
658 Pigazzi A et al. Multicentric study on robotic tumor-specific mesorectal excision for the treatment of rectal cancer. Ann Surg Oncol 2010; 17 (06) 1614-1620
659 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-374
660 Verwaal VJ et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21 (20) 3737-3743
661 Verwaal VJ et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15 (09) 2426-2432
662 Cao C et al. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16 (08) 2152-2165
663 Khot UP et al. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89 (09) 1096-1102
664 Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2010; 34 (04) 797-807
665 Poultsides GA et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27 (20) 3379-3384
666 Hermanek P, Guggenmoos-Holzmann I, Gall FP. Prognostic factors in rectal carcinoma. A contribution to the further development of tumor classification. Dis Colon Rectum 1989; 32 (07) 593-599
667 Hermanek P, Hohenberger W. The importance of volume in colorectal cancer surgery. Eur J Surg Oncol 1996; 22 (03) 213-215
668 Compton CC. Pathology report in colon cancer: what is prognostically important?. Dig Dis 1999; 17 (02) 67-79
669 Wong JH et al. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17 (09) 2896-2900
670 Compton C et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88 (07) 1739-1757
671 Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124 (07) 1016-1025
672 Hermanek P. Methodik der histopathologischen Untersuchung von Resektionen kolorektaler Karzinome. Chir Gastroenterol 2000; 16: 255-259
673 Hermanek P. Lymph nodes and malignant tumors. Zentralbl Chir 2000; 125 (10) 790-795
674 Junginger THP, Klimpfinger M. Klassifikation maligner Tumoren des Gastrointestinaltraktes I. Berlin Heidelberg New York: Springer Verlag; 2002
675 Wittekind C et al. TNM residual tumor classification revisited. Cancer 2002; 94 (09) 2511-2516
676 Leibl S, Tsybrovskyy O, Denk H. How many lymph nodes are necessary to stage early and advanced adenocarcinoma of the sigmoid colon and upper rectum?. Virchows Arch 2003; 443 (02) 133-138
677 Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003; 21 (01) 19-22
678 Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12 (01) 19-23
679 Wright CM et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000; 87 (09) 1197-1202
680 Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23 (03) 609-618
681 Benatti P et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005; 11 (23) 8332-8340
682 Malesci A et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007; 13 (13) 3831-3839
683 Leopoldo S et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 2008; 15 (05) 1429-1439
684 Lanza G et al. Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival. J Clin Oncol 1999; 17 (08) 2429-2438
685 Parc Y et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004; 53 (03) 371-375
686 Gafa R et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000; 89 (10) 2025-2037
687 Lanza G et al. Immunohistochemical pattern of MLH1 / MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002; 15 (07) 741-749
688 Lindor NM et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20 (04) 1043-1048
689 Overbeek LI et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 2008; 32 (08) 1246-1251
690 Prandi M et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002; 235 (04) 458-463
691 Ogino S et al. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol 2010; 105 (02) 420-433
692 Swanson RS et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10 (01) 65-71
693 Carloss H et al. The impact of number of lymph nodes removed on five-year survival in stage II colon and rectal cancer. J Ky Med Assoc 2004; 102 (08) 345-347
694 Fazio L et al. Association between colonic screening, subject characteristics, and stage of colorectal cancer. Am J Gastroenterol 2005; 100 (11) 2531-2539
695 Wong SL et al. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007; 298 (18) 2149-2154
696 Qiu HB et al. Ratio of metastatic to resected lymph nodes enhances to predict survival in patients with stage III colorectal cancer. Ann Surg Oncol 2011; 18 (06) 1568-1574
697 Wang J et al. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?. Ann Surg 2009; 249 (04) 559-563
698 Chen SL et al. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg 2011; 253 (01) 82-87
699 Ha YH et al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann Surg 2010; 252 (02) 336-340
700 West NP et al. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010; 28 (02) 272-278
701 West NP et al. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol 2008; 9 (09) 857-865
702 Quirke P et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373 (9666) 821-828
703 Tilney HS et al. The influence of circumferential resection margins on long-term outcomes following rectal cancer surgery. Dis Colon Rectum 2009; 52 (10) 1723-1729
704 Bernstein TE et al. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009; 96 (11) 1348-1357
705 West NP et al. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol 2008; 26 (21) 3517-3522
706 Leite JS et al. Clinical significance of macroscopic completeness of mesorectal resection in rectal cancer. Colorectal Dis 2011; 13 (04) 381-386
707 Kreienberg R et al. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Informationszentrum für Standards in der Onkologie (ISTO), Deutsche Krebsgesellschaft e.V. 2008; 1. Aktualisierung
708 Edwards AG, Hailey S, Maxwell M. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 2004; 2: CD004253
709 Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 1999; 80 (11) 1770-1780
710 Keller M et al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. Ann Oncol 2004; 15 (08) 1243-1249
711 Sharpe M et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 2004; 90 (02) 314-320
712 Singer S, Das-Munshi J, Brahler E. Prevalence of mental health conditions in cancer patients in acute care – a meta-analysis. Ann Oncol 2010; 21 (05) 925-930
713 Zabora J et al. The prevalence of psychological distress by cancer site. Psychooncology 2001; 10 (01) 19-28
714 Jansen L et al. Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. J Clin Oncol 2011; 29 (24) 3263-3269
715 Lynch BM et al. Describing and predicting psychological distress after colorectal cancer. Cancer 2008; 112 (06) 1363-1370
716 Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007; 110 (08) 1665-1676
717 Ramsey SD et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88 (06) 1294-1303
718 Zettl S, Hartlapp J (eds.) Sexualstörungen durch Krankheit und Therapie. Heidelberg: ed. Springer; 1997: S. 59
719 Fallowfield L et al. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 2001; 84 (08) 1011-1015
720 Sollner W et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?. Br J Cancer 2001; 84 (02) 179-185
721 Ell K et al. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol 2008; 26 (27) 4488-4496
722 Strong V et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet 2008; 372 (9632) 40-48
723 Herschbach P, Weis J (eds.) Screeningverfahren in der Psychoonkologie. Berlin: Deutsche Krebsgesellschaft; 2008
724 NHMRC. Clinical practice guidelines for the psychosocial care of adults with cancer. 2003; 1-237
725 Turner J et al. Clinical practice guidelines for the psychosocial care of adults with cancer. Psychooncology 2005; 14 (03) 159-173
726 Weis J et al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin. Onkologe 2007; 13 (02) 185-194
727 Edwards AG, Hulbert-Williams N, Neal RD. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 2008; 3: CD004253
728 Faller H et al. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. Nat J Cancer in press.
729 Goedendorp MM et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009; 1: CD006953
730 Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin 2008; 58 (04) 214-230
731 Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psychooncology 2001; 10 (06) 490-502
732 Osborn RL, Demoncada AC, Feuerstein M. Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses. Int J Psychiatry Med 2006; 36 (01) 13-34
733 Rehse B, Pukrop R. Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies. Patient Educ Couns 2003; 50 (02) 179-186
734 Uitterhoeve RJ et al. Psychosocial interventions for patients with advanced cancer – a systematic review of the literature. Br J Cancer 2004; 91 (06) 1050-1062
735 Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006; 94 (03) 372-390
736 Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002; 20 (19) 3992-3998
737 Lonardi S, Stefani M, Jirillo A et al. Benefit of fluorouracil and folinic acid adjuvant in colon cancer. Journal of Clinical Oncology 2006; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 (Suppl. 18) Abstract 13564
738 Sargent DJ et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345 (15) 1091-1097
739 Popescu RA et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17 (08) 2412-2418
740 Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. Journal of Clinical Oncology 2006; 24 (25) 4085-4091
741 Fata F et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer 2002; 94 (07) 1931-1938
742 Francini G et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106 (04) 899-906
743 O’Connell MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15 (01) 246-250
744 Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997; 40 (01) 35-41
745 Gill S et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 2004; 22 (10) 1797-1806
746 Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345 (8955) 939-944
747 Figueredo A et al. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997; 1 (05) 379-392
748 Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17 (05) 1356-1363
749 Mamounas E et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17 (05) 1349-1355
750 Benson 3rd AB et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22 (16) 3408-3419
751 Quasar Collaborative G et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370 (9604) 2020-2029
752 Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Journal of Clinical Oncology 2007; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 25 (Suppl. 18) Abstract 4007
753 Moertel CG et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995; 13 (12) 2936-2943
754 Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85 (10) 1437-1443
755 Schrag D et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20 (19) 3999-4005
756 Merkel S et al. High-risk groups of patients with Stage II colon carcinoma. Cancer 2001; 92 (06) 1435-1443
757 Petersen VC et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer. Gut 2002; 51 (01) 65-69
758 Morris M et al. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006; 93 (07) 866-871
759 Burdy G et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44 (11) 1682-1688
760 Jestin P et al. Emergency surgery for colonic cancer in a defined population. Br J Surg 2005; 92 (01) 94-100
761 McArdle CS, McMillan DC, Hole DJ. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. Br J Surg 2006; 93 (04) 483-488
762 Caplin S et al. For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 1998; 83 (04) 666-672
763 George S et al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer 2006; 95 (07) 841-847
764 Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006; 244 (04) 602-610
765 Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322 (06) 352-358
766 Hermanek P, Hutter RV, Sobin LH. Prognostic grouping: the next step in tumor classification. J Cancer Res Clin Oncol 1990; 116 (05) 513-516
767 Martinez-Lopez E et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998; 114 (06) 1180-1187
768 Ogunbiyi OA et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998; 16 (02) 427-433
769 Jernvall P et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999; 79 (05) 903-908
770 Font A et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001; 44 (04) 549-557
771 Diep CB et al. Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol 2003; 21 (05) 820-829
772 Carethers JM et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114 (06) 1188-1195
773 Lanza G et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24 (15) 2359-2367
774 Sinicrope FA et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131 (03) 729-737
775 Araujo SE et al. DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 2007; 50 (11) 1800-1810
776 Ribic CM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349 (03) 247-257
777 Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001; 1 (02) 104-109
778 Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350 (23) 2343-2351
779 Kuebler JP et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25 (16) 2198-2204
780 Schmoll HJ et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25 (01) 102-109
781 Van Cutsem E, Labianca R, Hossfeld D et al. PETACC 3, Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3). Journal of Clinical Oncology 2005; ASCO Annual Meeting Proceedings Abstract LBA8
782 Ychou M, Raoul J, Douillard J et al. , for the GI Group of the FNCLCC and the FFCD A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02 / FFCD9802). Journal of Clinical Oncology 2005; ASCO Annual Meeting Proceedings 2005 23: Abstract 3502 (Suppl 16, Part I of II):
783 Saltz LB et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25 (23) 3456-3461
784 Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352 (26) 2696-2704
785 Lembersky BC et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24 (13) 2059-2064
786 Sakamoto J et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22 (03) 484-492
787 Carrato A, Köhne C, Bedenne L et al. for AIO/CAO, FFCD, TTD, EORTC olinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. F. Journal of Clinical Oncology 2006; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006; 24 (Suppl 18): Abstract 3563
788 Andre T, Quinaux E, Louvet C et al. GERCOR. Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients. Journal of Clinical Oncology 2005; . ASCO Annual Meeting Proceedings. 2005 23 (Suppl 16): Abstract 3522
789 Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21 (15) 2896-2903
790 Arkenau HT, Rettig K, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 2005; 20 (03) 258-261
791 Chau I et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16 (04) 549-557
792 Poplin EA et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23 (09) (Suppl. 05) 1819-1825
793 O’Connell MJ et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16 (01) 295-300
794 Haller DG et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23 (34) 8671-8678
795 Kapiteijn E et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (09) 638-646
796 Rodel C, Sauer R. Neoadjuvant radiotherapy and radiochemotherapy for rectal cancer. Recent Results Cancer Res 2005; 165: 221-230
797 Peeters KC et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246 (05) 693-701
798 Folkesson J et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23 (24) 5644-5650
799 Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol 2007; 25 (08) 1014-1020
800 Rengan R et al. Distal cT2N0 rectal cancer: is there an alternative to abdominoperineal resection?. J Clin Oncol 2005; 23 (22) 4905-4912
801 Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358 (9290) 1291-1304
802 Camma C et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Jama 2000; 284 (08) 1008-1015
803 Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993; 36 (06) 564-572
804 Sauer R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351 (17) 1731-1740
805 Marijnen CA et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23 (09) 1847-1858
806 Peeters KC et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients – a Dutch colorectal cancer group study. J Clin Oncol 2005; 23 (25) 6199-6206
807 Junginger T et al. Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication. Zentralbl Chir 2006; 131 (04) 275-284
808 Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008; 47: 20-31
809 Sebag-Montefiore D, Stephens R, Quirke P et al. for the NCRI colorectal cancer study group and CRO 7 participants Routine short course pre-op radiotherapy or selective post-op chemoradiotherapy for resectable rectal cancer? Preliminary results of the MRC CR07 randomised trial. Journal of Clinical Oncology 2006; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2006 24 (Suppl. 18) Abstract 3511
810 Bujko K et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72 (01) 15-24
811 Bujko K et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93 (10) 1215-1223
812 Marijnen CA et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19 (07) 1976-1984
813 Bosset JF et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355 (11) 1114-1123
814 Gerard JP et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24 (28) 4620-4625
815 Rodel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol 2007; 183 (05) 227-235
816 Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985; 312 (23) 1465-1472
817 Krook JE et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324 (11) 709-715
818 Merkel S, Mannsmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16: 298-304
819 Gunderson LL, Sargent DJ, Tepper JE et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys 2002; 54: 386-96
820 Marijnen CA et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55 (05) 1311-1320
821 O’Connell MJ et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507
822 Smalley SR et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24 (22) 3542-3547
823 Tepper JE et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control – final report of intergroup 0114. J Clin Oncol 2002; 20 (07) 1744-1750
824 Lee JH et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol 2002; 20 (07) 1751-1758
825 Kim BITK, Lee J, Lee J et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: A final report. ASCO Meeting Abstracts 2007; 25: 4050
826 Rodel C, Sauer R. Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004; 13 (02) 93-101
827 Akasu T et al. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36 (04) 237-244
828 Collette L, Bosset J, den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007; 25: 4379-4386
829 Lehnert T, Knaebel H, Duck M et al. Sequential hepatic and pulmonary resections for metastatic colorectal cancer. Br J Surg 1999; 86: 241-243
830 Saito Y et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg 2002; 124 (05) 1007-1013
831 Pfannschmidt J et al. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 2003; 126 (03) 732-739
832 Lee WS et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis 2007; 22 (06) 699-704
833 Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007; 84 (01) 324-338
834 Poston GJ et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23 (28) 7125-7134
835 Nordlinger B et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77 (07) 1254-1262
836 Fong Y et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15 (03) 938-946
837 Scheele J et al. Resection of colorectal liver metastases. What prognostic factors determine patient selection?. Chirurg 2001; 72 (05) 547-560
838 Kato T et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 2003; 46 (Suppl. 10) S22-S31
839 Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230 (03) 309-318 ; discussion 318-321
840 Schmiegel W et al. Update S3-guideline “colorectal cancer” 2008. Z Gastroenterol 2008; 46 (08) 799-840
841 Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371 (9617) 1007-1016
842 Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23 (09) 2038-2048
843 Lorenz M et al. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl Chir 2003; 128 (02) 87-94
844 Wein A et al. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003; 64 (02) 131-138
845 Gruenberger B et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26 (11) 1830-1835
846 Langer B, Bleiberg H, Labianca R et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002; 21 (abstr 592)
847 Mitry E, Fields A, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials. Journal of Clinical Oncology 2006; ASCO Annual Meeting Proceedings Part I 2006; 24 (Suppl. 18) Abstract 3524
848 Portier G et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24 (31) 4976-4982
849 Parks R et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204 (05) 753-761 ; discussion 761-763
850 Figueras J et al. Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases. Br J Surg 2001; 88 (07) 980-985
851 Scheithauer W et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Bmj 1993; 306 (6880) 752-755
852 Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10 (06) 904-911
853 Mattioli R et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16 (07) 1147-1151
854 Feliu J et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94 (07) 969-975
855 Sastre J et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005; 23 (15) 3545-3551
856 Barrueco J, Marshall J, Mitchell E et al. Safety and efficacy of first-line irinotecan/fluoropymidine combinations in mCRC patients >65 years compared with those <65: The BICC-C study. Journal of Clinical Oncology 2007; ASCO Annual Meeting Proceedings Part I 2007; 25 (Suppl. 18) Abstract 4076
857 Folprecht G, Seymour MT, Saltz L et al. Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. Journal of Clinical Oncology 2008; 26 (09) 1443-1451
858 Giacchetti S et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10 (06) 663-669
859 Falcone A et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25 (13) 1670-1676
860 Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Journal of Clinical Oncology 2007; . ASCO Annual Meeting Proceedings Part I 2007 25 (Suppl. 18) Abstract 4000
861 Van Cutsem E, Lang I, D’haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 (abstr 2)
862 Folprecht G et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16 (08) 1311-1319
863 Souglakos J et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs. FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94 (06) 798-805
864 Saltz LB et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12) 2013-2019
865 Aloia T et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24 (31) 4983-4990
866 Vauthey JN et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24 (13) 2065-2072
867 Benoist S et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 2006; 24 (24) 3939-3945
868 Koopman M et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370 (9582) 135-142
869 Schmoll HJ, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. Lancet 2007; 370 (9582) 105-107
870 Seymour MT et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370 (9582) 143-152
871 Dy GK et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 2007; 25 (23) 3469-3474
872 Grothey A et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22 (07) 1209-1214
873 Petrelli N et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7 (10) 1419-1426
874 Poon MA et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7 (10) 1407-18
875 Lokich JJ et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7 (04) 425-432
876 Gramont A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15 (02) 808-815
877 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16 (01) 301-308
878 Clarke DE, Raffin TA. Infectious complications of indwelling long-term central venous catheters. Chest 1990; 97 (04) 966-972
879 Prandoni P et al. Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216). Haemostasis 1990; 20 (Suppl. 01) 220-223
880 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21 (19) 3665-3675
881 Liu G et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15 (01) 110-115
882 Borner MM et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002; 38 (03) 349-358
883 Twelves C et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006; 17 (02) 239-245
884 Van Cutsem E et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19 (21) 4097-4106
885 Hoff PM et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19 (08) 2282-2292
886 Van Cutsem E et al. Oral capecitabine vs. intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90 (06) 1190-1197
887 Kohne CH et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13 (02) 308-317
888 Gramont A et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16) 2938-2947
889 Giacchetti S et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24 (22) 3562-3569
890 Giacchetti S et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18 (01) 136-147
891 Douillard JY et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355 (9209) 1041-1047
892 Kohne CH et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23 (22) 4856-4865
893 Saltz LB et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343 (13) 905-914
894 Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22 (02) 229-237
895 Colucci G et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005; 23 (22) 4866-4875
896 Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22 (01) 23-30
897 Goldberg RM et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24 (21) 3347-3353
898 Comella P et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i. v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i. v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 2005; 16 (06) 878-886
899 Diaz-Rubio E et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25 (27) 4224-4230
900 Porschen R et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25 (27) 4217-4223
901 Cassidy J et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26 (12) 2006-2012
902 Fuchs CS et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25 (30) 4779-4786
903 Kohne CH et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19 (05) 920-926
904 Schmiegel WH, Reinacher-Schick A, Freier W et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. Journal of Clinical Oncology 2007; ASCO Annual Meeting Proceedings Part I 2007 25 (Suppl. 18) 4034
905 Kabbinavar FF et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23 (16) 3697-3705
906 Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23) 2335-2342
907 Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study. Journal of Clinical Oncology 2007; ASCO Annual Meeting Proceedings Part I 2007 25 (Suppl. 18) 4035
908 Folprecht G et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006; 17 (03) 450-456
909 Tournigand C et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006; 24 (03) 394-400
910 Maindrault-Goebel F, Lledo G, Chibaudel B et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. Journal of Clinical Oncology 2007; ASCO Annual Meeting Proceedings Part I 2007 25 (Suppl. 18) 4013
911 Maughan TS et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361 (9356) 457-464
912 Labianca R et al. Alternating versus continuous “FOLFIRI” in advanced colorectal cancer (ACC): A randomized “GISCAD” trial. Journal of Clinical Oncology 2006; ASCO Annual Meeting Proceedings Part I 2006; 24 (Suppl 18)
913 Cunningham D et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352 (9138) 1413-1418
914 Rougier P et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352 (9138) 1407-1412
915 Rothenberg ML et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21 (11) 2059-2069
916 Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351 (04) 337-345
917 Sobrero AF et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26 (14) 2311-2319
918 Giantonio BJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25 (12) 1539-1544
919 Rothenberg ML et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). Journal of Clinical Oncology 2007; ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2007 25 (Suppl. 18)
920 Eng C, Maurel J, Scheithauer W et al. Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: the EPIC trial. Proc Am Soc Clin Oncol 2007; 25: 164s Abstract 4003
921 Rao S et al. Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 2004; 91 (05) 839-843
922 Chong G et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005; 93 (05) 510-514
923 Lim DH et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005; 56 (01) 10-14
924 Alliot C. Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2006; 94 (06) 935-936 ; author reply 937
925 Lenz HJ et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24 (30) 4914-4921
926 Jonker DJ, O’Callaghan CJ, Karapetis CS et al. Cetuximab for the Treatment of Colorectal Cancer. N Engl J Med 2007; 357: 2040-2048
927 Lievre A et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26 (03) 374-379
928 Hecht JR et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110 (05) 980-988
929 Van Cutsem E et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25 (13) 1658-1664
930 Amado RG, Wolf M, Peeters M et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology 2008; 26 (10) 1626-1634
931 Lehnert T, Golling M. Posterior pelvic exenteration in locoregional recurrence of rectal carcinoma – indications, technique and outcome. Chirurg 2001; 72 (12) 1393-1401
932 Shibata D et al. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum 2002; 45 (06) 795-801
933 Wu JS et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55 (03) 594-605
934 Farnell GF et al. Brain metastases from colorectal carcinoma. The long term survivors. Cancer 1996; 78 (04) 711-716
935 Schoeggl A et al. Stereotactic radiosurgery for brain metastases from colorectal cancer. Int J Colorectal Dis 2002; 17 (03) 150-155
936 Enblad P et al. The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study. Cancer 1990; 65 (09) 2091-2100
937 Cali RL et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum 1993; 36 (04) 388-393
938 Hermanek PJr et al. Long-term results of surgical therapy of colon cancer. Results of the Colorectal Cancer Study Group. Chirurg 1994; 65 (04) 287-297
939 Yamazaki T et al. What is the risk factor for metachronous colorectal carcinoma?. Dis Colon Rectum 1997; 40 (08) 935-938
940 Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10 (07) 793-798
941 Green RJ et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002; 136 (04) 261-269
942 Harris GJ et al. Factors affecting local recurrence of colonic adenocarcinoma. Dis Colon Rectum 2002; 45 (08) 1029-1034
943 Merkel S et al. Late locoregional recurrence in rectal carcinoma. Eur J Surg Oncol 2002; 28 (07) 716-722
944 Poulin EC et al. Local recurrence and survival after laparoscopic mesorectal resection forrectal adenocarcinoma. Surg Endosc 2002; 16 (06) 989-995
945 Bulow S et al. Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg 2003; 90 (08) 974-980
946 Secco GB et al. Factors influencing incidence and extension of metachronous liver metastases of colorectal adenocarcinoma. A multivariate analysis. Hepatogastroenterology 1997; 44 (16) 1057-1062
947 Pietra N et al. Risk factors of local recurrence of colorectal cancer: a multivariate study. Hepatogastroenterology 1998; 45 (23) 1573-1578
948 Scholmerich J. Sense and nonsense in after-care of colorectal carcinoma. Med Klin (Munich) 1996; 91 (06) 420-427
949 Kievit J. Colorectal cancer follow-up: a reassessment of empirical evidence on effectiveness. Eur J Surg Oncol 2000; 26 (04) 322-328
950 Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur J Cancer 2002; 38 (07) 986-999
951 Wichmann MW et al. Results of long-term follow-up after curative resection of Dukes A colorectal cancer. World J Surg 2002; 26 (06) 732-736
952 Yamamoto S et al. Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: is follow-up by CEA justified?. Hepatogastroenterology 2005; 52 (62) 444-449
953 Korner H et al. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg 2005; 9 (03) 320-328
954 Talbot IC et al. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980; 67 (06) 439-442
955 Minsky BD et al. Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion. Cancer 1988; 61 (07) 1417-1424
956 Krasna MJ et al. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988; 61 (05) 1018-1023
957 Inoue T et al. Vascular invasion of colorectal carcinoma readily visible with certain stains. Dis Colon Rectum 1992; 35 (01) 34-39
958 Bruinvels DJ et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219 (02) 174-182
959 Rosen M et al. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 1998; 41 (09) 1116-1126
960 Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002; 1: CD002200
961 Renehan AG et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Bmj 2002; 324 (7341) 813
962 Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995; 130 (10) 1062-1067
963 Ohlsson B et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38 (06) 619-626
964 Kjeldsen BJ et al. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997; 84 (05) 666-669
965 Pietra N et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998; 41 (09) 1127-1133
966 Schoemaker D et al. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114 (01) 7-14
967 Secco GB et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002; 28 (04) 418-423
968 Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007; 1: CD002200
969 Wattchow DA et al. General practice vs. surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 2006; 94 (08) 1116-1121
970 Rodriguez-Moranta F et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006; 24 (03) 386-393
971 Laubert T et al. Intensified surveillance after surgery for colorectal cancer significantly improves survival. Eur J Med Res 2010; 15 (01) 25-30
972 Papagrigoriadis S, Heyman B. Patients’ views on follow up of colorectal cancer: implications for risk communication and decision making. Postgrad Med J 2003; 79 (933) 403-407
973 Cooper GS, TD Kou, HL ReynoldsJr. Receipt of guideline-recommended follow-up in older colorectal cancer survivors: a population-based analysis. Cancer 2008; 113 (08) 2029-2037
974 Rocklin MS, Slomski CA, Watne AL. Postoperative surveillance of patients with carcinoma of the colon and rectum. Am Surg 1990; 56 (01) 22-27
975 Benson 3rd AB et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 2000; 18 (20) 3586-3588
976 Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet 2000; 355 (9201) 395-399
977 Desch CE et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999; 17 (04) 1312
978 Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999; 26 (05) 556-560
979 Duffy MJ et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39 (06) 718-727
980 Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001; 47 (04) 624-630
981 Moertel CG et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. Jama 1993; 270 (08) 943-947
982 Safi F, Beyer HG. The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev 1993; 17 (03) 417-424
983 Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum 1993; 36 (11) 1063-1068
984 Huebner RH et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41 (07) 1177-1189
985 Annovazzi A et al. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology 2003; 125 (04) 1235-1245
986 Ahlquist DA et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. Jama 1993; 269 (10) 1262-1267
987 Hunerbein M et al. The role of transrectal ultrasound-guided biopsy in the postoperative follow-up of patients with rectal cancer. Surgery 2001; 129 (02) 164-169
988 Mitry E et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010; 59 (10) 1383-1388
989 Desch CE et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23 (33) 8512-8519
990 Chau I et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22 (08) 1420-1429
991 Sugarbaker PH et al. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987; 102 (01) 79-87
992 Wang T et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointest Endosc 2009; 69 (03) 609-615
993 Rulyak SJ et al. Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients. Clin Gastroenterol Hepatol 2007; 5 (04) 470-476 ; quiz 407
994 Rex DK et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130 (06) 1865-1871
995 Bouvier AM et al. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer 2008; 44 (04) 522-527
996 Sobhani I et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008; 98 (05) 875-880
997 Selvaggi F et al. FGD-PET in the follow-up of recurrent colorectal cancer. Colorectal Dis 2003; 5 (05) 496-500
998 Eckardt VF, Bernhard G. Nachsorge beim kolorektalen Karzinom. Eine Analyse von Effektivität und Kosten. Deutsches Ärzteblatt 1997; 94: A456-A462
999 Schwibbe G. Changes in quality of life in oncological patients in the course of an inpatient after-care program. Rehabilitation (Stuttg) 1991; 30 (02) 55-62
1000 Gartner U et al. Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation. Med Klin (Munich) 1996; 91 (08) 501-508
1001 Etzioni DA, El-Khoueiry AB, Beart Jr RW . Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 2008; 113 (12) 3279-3289
1002 Grothey A, Kellermann L, Schmoll HJ. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin (Munich) 2002; 97 (05) 270-277
1003 von der Schulenburg JM, Prenzler A, Schurer W. Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer. Eur J Health Econ 2010; 10 (Suppl. 01) S21-S26
1004 Adler G, Seufferlein T. Hope and disappointment in cancer medicine. Z Arztl Fortbild Qualitatssich 2007; 101 (05) 287-292
1005 Harrison JD et al. What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer 2009; 17: 1117-1128
1006 Lewis R et al. Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. J Adv Nurs 2009; 65 (04) 706-723
1007 Howell DM et al. A mixed-method evaluation of nurse-led community-based supportive cancer care. Support Care Cancer 2008; 16 (12) 1343-1352
1008 Ouwens M et al. Implementation of integrated care for patients with cancer: a systematic review of interventions and effects. Int J Qual Health Care 2009; 21 (02) 137-144
1009 Jahn P et al. Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. Support Care Cancer 2009; 17 (12) 1543-1552
1010 Jahn P et al. Improvement of pain related self management for oncologic patients through a trans institutional modular nursing intervention: protocol of a cluster randomized multicenter trial. Trials 2010; 11: 29
1011 Chen RC et al. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer 2010; 116 (08) 1879-1886
1012 Meyerhardt JA et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 2008; 26 (25) 4109-4115
1013 Meyerhardt JA et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006; 24 (22) 3527-3534
1014 Meyerhardt JA et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006; 24 (22) 3535-3541
1015 Ng K et al. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2010; 28 (28) 4354-4363
1016 Stumpf C et al. Retrospektive Untersuchung zur Therapie mit Mistelextrakten bei Patienten mit kolorektalem Karzinom. Dtsch Zschr Onkol 2007; 39: 12-22
1017 Friedel W et al. Fermented Europaen mistletoe (Viscum album L.) extract in supportive care in patients with primary non-metastatic colorectal cancer. In: Scheer R, , et al., (eds.) Die Mistel in der Tumortherapie. Essen: KVC Verlag; 2009: 563-576
1018 Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010; 9 (02) 142-157
1019 Shimizu M et al. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila) 2008; 1 (04) 298-304
1020 Hoensch H et al. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol 2008; 14 (14) 2187-2193
1021 Ito K et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 2004; 19 (02) 157-164
1022 Sakamoto J et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006; 55 (04) 404-411
1023 Kassab S et al. Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database Syst Rev 2009; 2: CD004845
1024 Rahbari NN et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 2010; 147 (03) 339-351
1025 Vasen HF et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116 (06) 1453-1456